a r t I C l e S Myelin, the insulating membrane that is produced by Schwann cells in the PNS and by oligodendrocytes in the CNS, is an organelle whose assembly and function is crucial for proper transmission of the electric impulse. Myelination in the PNS is controlled at the molecular level by the amount of axonal NRG1 type III 1,2 . Thus, clarifying the mechanisms that control NRG1 type III expression is essential to establish the molecular events that regulate myelin formation. The β-secretase BACE1 (refs. 3-5) and the α-secretases belonging to the ADAM family of proteases 6 control the classical regulated proteolysis of NRG1. Although the role of BACE1 in NRG1 type III cleavage has been investigated during myelination and remyelination 3-5 , the role of the α-secretases is unclear.
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ADAM (a disintegrin and metalloprotease) proteins are a family of zinc-dependent, membrane-anchored metalloproteases that are implicated in ectodomain shedding of several growth factors. ADAMs control myogenesis, neurogenesis, fertilization, inflammation and myelination 6 . Several members of the ADAM secretases are expressed in the PNS, and some have been implicated in myelination. In particular, ADAM19 can process NRG1 (ref. 7) , although recent studies suggest that ADAM19 targets NRG1 type I 8 , which is not implicated in myelination 1, 2 . Accordingly, mice lacking ADAM19 myelinate normally, although they have delayed remyelination 9 . Another ADAM that is directly implicated in myelination is ADAM22, as transgenic mice lacking ADAM22 are hypomyelinated in the PNS 10 . However, it is unlikely that ADAM22 cleaves NRG1 type III or other growth factors, as this protein lacks a catalytic-site consensus sequence 6 . Rather, axonal ADAM22 functions as a receptor for secreted LGI4 (leucine-rich repeat LGI family, member 4) 11 . Recently, the role of ADAM10 in NRG1 cleavage was analyzed. However, mice with altered ADAM10 expression myelinate normally in the PNS 12 , suggesting that ADAM10 is dispensable for this process.
Another member of this family, TACE, has been implicated in NRG1 cleavage 13 . TACE mediates ectodomain shedding of several membrane-bound molecules, including tumor necrosis factor-α (TNF-α), transforming growth factor-α (TGF-α), p75 neurotrophin receptor (p75 NTR ; also known as NGFR), Notch and amyloid precursor protein (APP) 6, 14 in addition to NRG1. Transgenic mice lacking TACE die at birth, preventing the analysis of myelination in vivo 15 . We now report that TACE cleaves NRG1 type III and that ablation of TACE results in altered processing of axonal NRG1 type III. In addition, downregulation of TACE expression in vitro in myelinating cocultures and inactivation of TACE in vivo in motor neurons lead to precocious myelination, hypermyelination, ectopic myelination and enhanced activation of the phosphatidylinositol-3-OH kinase (PI3K) pathway. Furthermore, the reduction of TACE activity in vivo is sufficient to rescue myelination of NRG1 type III haploinsufficient mice. We also provide evidence that this phenotype is due to a cell-autonomous mechanism, as inactivation of TACE in Schwann cells in vitro and in vivo does not alter the timing of myelin production or the amount produced.
Thus, our study reveals a previously uncharacterized role for TACE in myelination. By cleaving NRG1 type III, TACE determines the amount of this critical regulator of myelination on the axonal surface and, unlike BACE1 (refs. 3,5) , negatively regulates PNS myelination. To our knowledge, this is the first study reporting a negative mechanism for controlling NRG1 type III expression and myelination, further suggesting that secretases are important modulators of myelination. Tumor necrosis factor--converting enzyme (TACE; also known as ADAM17) is a proteolytic sheddase that is responsible for the cleavage of several membrane-bound molecules. We report that TACE cleaves neuregulin-1 (NRG1) type III in the epidermal growth factor domain, probably inactivating it (as assessed by deficient activation of the phosphatidylinositol-3-OH kinase pathway), and thereby negatively regulating peripheral nervous system (PNS) myelination. Lentivirus-mediated knockdown of TACE in vitro in dorsal root ganglia neurons accelerates the onset of myelination and results in hypermyelination. In agreement, motor neurons of conditional knockout mice lacking TACE specifically in these cells are significantly hypermyelinated, and small-caliber fibers are aberrantly myelinated. Further, reduced TACE activity rescues hypomyelination in NRG1 type III haploinsufficient mice in vivo. We also show that the inhibitory effect of TACE is neuron-autonomous, as Schwann cells lacking TACE elaborate myelin of normal thickness. Thus, TACE is a modulator of NRG1 type III activity and is a negative regulator of myelination in the PNS. a r t I C l e S
TACE (ADAM17) inhibits Schwann cell myelination
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RESULTS

TACE inactivation enhances myelination in vitro
To investigate the role of TACE in myelination, we first analyzed its mRNA and protein levels in vitro. TACE is highly expressed in Schwann cells and, at lower levels, in dorsal root ganglia (DRG) neurons, as shown by PCR with reverse transcription (RT-PCR) and western blot analyses of cDNAs or lysates prepared from Schwann cells and DRG neurons (Supplementary Fig. 1) .
Tace −/− (Adam17 −/− ) mice die at birth 15 , precluding in vivo analysis of myelination. To determine the role of TACE in myelin formation, we first knocked down its expression using specific short hairpin RNA (shRNA)-encoding lentiviruses. For our studies, we used three different shRNA clones (TRCN0000031949, TRCN0000031952 and TRCN0000031953) that were obtained from the RNAi Consortium (Boston, Massachusetts, USA) together with a lentiviral vector expressing a scrambled artificial sequence as a negative control. Database searches confirmed that the sequence used in the scrambled shRNA did not recognize any mammalian DNA. To validate the specificity of Tace-targeting shRNAs, we tested their ability to modulate the cleavage of p75 NTR and Notch1. Both molecules are important in myelination 16, 17 , but only p75 NTR is cleaved by TACE 18 , whereas Notch1 is extracellularly processed by ADAM10 (refs. 19,20) .
As expected, we observed impaired p75 NTR cleavage in Schwann cell-DRG neuron cocultures infected with lentiviruses encoding Tace shRNAs, but the amount of Notch1 intracellular domain (NICD) was unaltered ( Supplementary Fig. 2) .
To corroborate the efficacy of knockdown, we infected primary rat Schwann cells for 2 d and then analyzed expression by western blotting on an Odyssey imaging system (Fig. 1a) . All three tested shRNAs significantly decreased TACE expression by approximately 80% when compared with mock-infected or control uninfected Schwann cells (Fig. 1b) . We then infected mouse DRG explant cultures, which contain a mix of Schwann cells and DRG neurons, with lentiviruses encoding Tace shRNA or a scrambled shRNA for 48 h. The cultures were grown without antimitotic agents to allow infection of both neurons and Schwann cells. Western blots confirmed effective TACE knockdown of infected cultures (data not shown). Myelination was induced by supplementing the cultures with 50 µg ml −1 ascorbic acid. Immunofluorescence analyses ( Fig. 1) for myelin basic protein (MBP) and neurofilament showed that myelination was significantly greater in Tace shRNA-infected cultures and was already substantial 3 d after the addition of ascorbic acid. Thus, myelination in cocultures infected with Tace shRNA was greater and commenced earlier than myelination in scrambled shRNA-infected or control uninfected cultures, suggesting that TACE inhibits myelination. To further confirm this result, we counted the number of MBP-positive segments 3 d after ascorbic acid addition in Tace shRNA-infected versus uninfected or scrambled shRNA-infected cultures. Specific knockdown of Tace led to an approximately 15-fold increase in myelination (Fig. 1c) . Western blotting for myelin proteins confirmed the hypermyelination. Fourteen days after the induction of myelination, myelin protein zero (MPZ) was appreciably upregulated in cocultures infected with lentiviruses encoding Tace shRNA (Fig. 1d) . As Tace knockdown resulted in enhanced and precocious myelination, our data suggest that TACE controls the temporal activation of the myelinating program.
TACE activity in vitro is neuron-autonomous
These results indicate that TACE negatively controls myelination. As both Schwann cells and DRG neurons express TACE, we sought to determine whether these effects are specific to Schwann cells, neurons or both using a purified myelinating coculture system. We first infected mouse DRG neurons with lentiviruses encoding Tace shRNA or, as a control, with lentiviruses encoding scrambled shRNA. We then cultured these neurons with primary uninfected rat Schwann cells and induced myelination for 15 d by ascorbic acid addition; cultures were then stained for MBP and neurofilament. In comparison with control neurons, DRG neurons that were knocked down for Tace were substantially hypermyelinated (Fig. 2a and Supplementary Fig. 3a) , and the a r t I C l e S number of myelinated segments in these neurons was approximately eightfold higher than the number in control neurons (Fig. 2b) . We did not observe any effect on neurite outgrowth. We confirmed these results with western blots of MBP, myelin-associated glycoprotein (MAG) and neurofilament expression. As expected, the expression of myelin proteins was notably upregulated in the lysates of cocultures that were ablated for neuronal Tace (data not shown).
In a parallel set of experiments, we inactivated Tace in rat primary Schwann cells and cultured them with purified uninfected mouse DRG neurons. Cultures were maintained in myelinating conditions for 21 d. Immunofluorescence for MBP and neurofilament ( Fig. 2c and Supplementary Fig. 3b ) and western blots for MBP and MAG (data not shown) indicated that inactivation of Tace in Schwann cells did not enhance myelination, strongly suggesting that the inhibitory role of TACE in myelination is neuronal cell-autonomous. These results were further confirmed by assessing the numbers of MBPpositive segments in these cultures, which were comparable between Tace knockdown and control cultures (Fig. 2d) . Thus, these studies indicate that TACE acts in a neuron-autonomous manner to inhibit myelination in an in vitro model of PNS myelination.
In vivo inactivation of axonal TACE causes hypermyelination
To evaluate the role of TACE in myelination during development and to determine whether neuronal TACE also inhibits myelination in vivo, we generated transgenic mice that lack TACE specifically in motor neurons. To this end, we crossed mice containing loxP sites flanking exon 2 of Tace ('floxed' Tace; Tace fl/fl ) 21 with the HB9-cre transgenic line, which has been used in previous studies to drive motor neuron-specific recombination using the promoter of the Mnx1 gene 22 . Ablation of Tace exon 2 leads to a functional null protein 21 . We screened the genotype by PCR analysis of genomic DNA that was prepared from the tail and spinal cord of HB9-cre; Tace fl/fl and wild-type controls (data not shown). As the HB9-cre transgene is expressed in motor neurons, we corroborated efficient recombination by determining Tace mRNA expression using RT-PCR on spinal cord of HB9-cre; Tace fl/fl and wild-type mice (Fig. 3a) . We also assessed TACE protein amounts in lysates that were prepared from postnatal day (P) 30 wild-type and HB9-cre; Tace fl/fl femoral nerves (Fig. 3b) . TACE expression was lower both at the mRNA and protein levels in HB9-cre; Tace fl/fl mice. Residual expression was probably due to un-recombined Tace that was present in other cells; in femoral nerves, these cells would be mainly Schwann cells and sensory nerve fibers.
Ultrastructural analysis of the ventral roots and sciatic nerves from newborn (P1) HB9-cre; Tace fl/fl mice showed that the onset of myelination in the ventral roots of these mice was accelerated (Fig. 3c) . As expected, we observed that some fibers in P1 sciatic nerves, which contain both sensory and motor fibers, were hypermyelinated (Fig. 3d) . Quantification of the number of myelinated fibers demonstrated that there were significantly more in HB9-cre; Tace fl/fl mice (P = 0.0039); the total number of nerve fibers was similar in both genotypes (Supplementary Table 1) .
To evaluate whether the hypermyelination of HB9-cre; Tace fl/fl mice is maintained during active phases of myelination, we analyzed peripheral nerve morphology in P7 and P15 sciatic nerves. At both time points, neurites were hypermyelinated, as evidenced in semithin sections (Fig. 4a,b , top panels) and in electron micrographs a r t I C l e S (Fig. 4a,b , lower panels). The hypermyelinating phenotype was also confirmed by g ratio (axon diameter/fiber diameter) measurements (Fig. 4c) , which showed that the g ratio of P7 fibers of sciatic nerves was significantly lower in HB9-cre; Tace fl/fl mice than in wild-type mice (Supplementary Table 1 ). This change did not result in altered fiber diameters in HB9-cre; Tace fl/fl , which were similar to those of wild-type mice (Fig. 4d) , strongly suggesting that the observed phenotype is due to changes in the myelin sheath. As suggested from our previous data, hypermyelination in HB9-cre; Tace fl/fl mice resulted in considerably more myelin lamellae surrounding fibers of similar caliber, with no alteration to myelin periodicity (Fig. 4e) .
Morphological and ultrastructural analysis of P30 HB9-cre; Tace fl/fl ventral roots (Fig. 5a ) and sciatic nerves (Fig. 5b) and g ratio measurements in sciatic nerves ( Fig. 5 and Supplementary Table 1 ) confirmed hypermyelination in adult mice, strongly suggesting that this effect is maintained throughout development. Unexpectedly, we observed a significant number of myelinated fibers with axons of less than 1 µm diameter and markedly smaller axonal diameters for myelinated fibers in sciatic nerves of HB9-cre; Tace fl/fl , despite the total number of myelinated fibers being similar between genotypes (wild type, 1,717; HB9-cre; Tace fl/fl , 1,697) ( Fig. 5g and Supplementary Table 1 ). Whether this difference is due to ectopic myelination or constriction of axonal caliber will require further investigation. Nonetheless, this alteration is unlikely to explain the hypermyelination, as both in vitro and in vivo studies indicate that axonal diameter increases with myelin formation 23, 24 . Of note, we similarly observed myelin sheath surrounding several fibers whose diameter was less than 1 µm in ventral roots of HB9-cre; Tace Fig. 5a, asterisks) . To determine whether the myelin protein content parallels the hypermyelinating phenotype, we checked MBP expression in P15 and P30 femoral nerves of wild-type and HB9-cre; Tace fl/fl by Western blotting. As expected, hypermyelination was accompanied by higher MBP expression (Fig. 5c) . Of note, even amounts of phosphorylated AKT (p-AKT) (Fig. 5d) -a key effector of the PI3K pathway, which acts downstream of NRG1 type III 1 and is important for PNS myelination 25, 26 -were higher in P30 femoral nerves of HB9-cre; Tace fl/fl mice than in those of wild-type mice. Our ultrastructural analysis also showed that ablation of neuronal Tace altered the organization of C fibers, which are engulfed by nonmyelinated Schwann cells in Remak bundles. In fact, we observed unsorted and unmyelinated fibers that were larger than 1 µm in diameter in HB9-cre; Tace fl/fl Remak bundles (Fig. 5e, asterisks) , suggesting an impaired sorting process. Furthermore, in many cases Remak bundles lacked intervening Schwann cell processes, suggesting that TACE also affects the ensheathment process of non-myelinated fibers.
To test whether TACE haploinsufficiency induces hypermyelination, we generated a complete Tace +/− transgenic line by crossing Tace fl/fl mice with mice with a CMV-cre transgene that drives recombination in all cells 27 . Morphological analysis, g ratio measurements and western blotting for myelin proteins showed that Tace +/− P30 sciatic nerves were myelinated normally, indicating that residual TACE activity is sufficient to regulate myelin formation ( Supplementary  Fig. 4 and Supplementary Table 1) .
Only axonal TACE determines hypermyelination
To corroborate our previous results, which indicate that hypermyelination is due to a neuronal cell-autonomous mechanism, we deleted Tace in Schwann cells in vivo by crossing Tace-floxed transgenic mice with a Mpz-cre transgenic line (creating Mpz-cre; Tace fl/fl mice) 28 . We confirmed efficient recombination in genomic DNA of P15 sciatic nerves of Mpz-cre; Tace fl/fl mice by PCR analyses (Fig. 6a) . Myelination in P7 and P30 Mpz-cre; Tace fl/fl sciatic nerves was similar to that of wild-type control mice, as assessed by semithin sections (top panels in Fig. 6b,c) and ultrastructural analysis (lower panels in Fig. 6b,c) . This result was further confirmed by g ratio measurements (Fig. 6d) (Fig. 6e) . Surprisingly, despite the similar numbers of myelinated fibers in wild-type and Mpz-cre; Tace fl/fl mice (wild type, 1,298; Mpz-cre; Tace fl/fl , 1,244), axonal diameters were slightly greater in Mpz-cre; Tace fl/fl sciatic nerves ( Fig. 6f and Supplementary Table 1) . Furthermore, the myelinated fibers of Mpz-cre; Tace fl/fl mice had more periaxonal space and an accumulation of organelles in the inner cytoplasmic collar (Supplementary Fig. 5 ), suggesting that glial TACE may process molecules that are implicated in myelin compaction and/or adhesion.
Taken together, these in vivo analyses provide compelling evidence that neuronal TACE inhibits myelination in a cell-autonomous mechanism. Ablation of Tace in motor neurons accelerates the myelination process and results in hypermyelination, leading to a greater number of myelin lamellae than in wild-type fibers with similar caliber, and ectopic myelination of small-caliber fibers that would normally be unmyelinated. In addition, our findings indicate that glial TACE also participates in the myelinating process, although it does not regulate myelin thickness. a r t I C l e S lysates of wild-type, Tace +/− and Tace −/− DRG neurons prepared from embryonic day 14.5 embryos (Fig. 7a) and in lysates of P30 HB9-cre; Tace fl/fl femoral nerves (Fig. 7b) . In the absence of TACE, NRG1 processing was impaired, as there was more of the unprocessed proprotein form in HB9-cre; Tace fl/fl DRG neurons. Of note, unprocessed NRG1 pro-protein was absent in HB9-cre; Tace fl/fl femoral nerves and barely present in wild-type control extracts. This difference is likely to be due to altered NRG1 expression in DRG neurons in culture and in sciatic nerves 1 . More importantly, the amount of cleaved NRG1 was similarly greater in the absence of TACE, probably owing to enhanced activity of other secretases (such as BACE1).
TACE cleaves NRG1 and controls axonal NRG1 type III levels
To further confirm these data, we mapped the TACE cleavage site of NRG1 by mass spectrometry. To this end, we incubated 2 µg of human recombinant NRG1 containing the EGF β-exon domain (NRG β1), the most abundant NRG1 isoform expressed in the nervous system, with 1 µg of human recombinant TACE. The proteins were then separated on a Tris-tricine gel (to favor the resolution of low-molecular-mass bands) together with native, uncleaved recombinant NRG1 β1 for comparison (Fig. 7c) . The reaction generated a cleavage product of ~6 kDa, which was digested with endoproteinase Glu-C and analyzed by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry. In the MALDI-TOF spectrum, two potential C-terminal peptides were detected that did not correspond to endoproteinase Glu-C cleavage (Supplementary Fig. 6 ) and therefore derived from TACE activity (Fig. 7d) . These peptides, with masses of 1,858.812 Da and 2,294.057 Da, corresponded to the peptide sequences FTGDRCQNYVMASFY and FTGDRCQNYVMASFYKHLG, respectively, suggesting that TACE cleaves NRG1 β1 either upstream or in the β-exon of the EGF domain, 3-6 amino acids before the previously identified BACE1 site (Fig. 7e) 4 . In our analysis, we did not observe cleavage at the BACE1 site of NRG1.
To determine whether the activity of NRG1 type III is altered following TACE cleavage, we incubated wild-type, control and Tace −/− DRG neurons, obtained by crossing Tace +/− mice, with the receptor ERBB2-ERBB3 fused to the Fc portion of human immunoglobulin G (ERBB2-ERBB3-Fc); this chimeric protein binds to NRG1 type III molecules, the only NRG1 molecules that are expressed on the axonal surface 1 . Chimeric ERBB2-ERBB3-Fc bound more robustly to DRG neurons lacking TACE than to wild-type uninfected or controlshRNA-infected DRG neurons (Fig. 7f) . Similar results were obtained in DRG neurons in which Tace expression had been ablated by shRNA infection (Supplementary Fig. 7) . Inhibition of Tace expression resulted in an ~50% increase in the amount of NRG1 type III on the axonal surface (Fig. 7g) . These results confirm that TACE cleaves NRG1 and suggest that TACE inhibits myelination by limiting the amount of functional NRG1 type III on the axonal surface.
TACE alters NRG1 type III signaling and myelination
Despite the key role of NRG1 type III in myelination, this is not the sole NRG1 isoform to be expressed by DRG neurons. In particular, DRG neurons also express NRG1 type I 29 , which is also processed by α-secretases 1 and has an amino acid sequence that is identical to that of NRG1 type III in the region cleaved by TACE. Thus, TACE could affect myelination by inhibiting the processing of NRG1 type I. Similarly, TACE could process other molecules that regulate myelin formation.
To further investigate the role of TACE-specific processing of NRG1 type III, we downregulated TACE activity in neurons in which the NRG1 type III isoform was disrupted (Nrg1 type III -/-neurons) ( Supplementary  Fig. 8b ) and investigated whether ablation of Tace could rescue myelination in these neurons 1 . We infected Nrg1 type III −/− DRG neurons with Tace-specific shRNA or with a scrambled shRNA control and rid a r t I C l e S the cultures of endogenous Schwann cells and fibroblasts ( Fig. 8 and Supplementary Fig. 8a ). We then repopulated the neurons with rat primary Schwann cells and, 21 d after the induction of myelination, we examined MBP and neurofilament expression by immunofluorescence (Fig. 8a) and western blot (Supplementary Fig. 8c ) analyses. Ablation of Tace in Nrg1 type III -/-neurons did not rescue myelination (Fig. 8) .
As PI3K is a key effector of NRG1 signaling and myelination, we tested whether NRG1 cleaved by TACE or BACE1 modulated this pathway. Thus, we incubated NRG1 β1 with recombinant human TACE or BACE1 and determined p-AKT activation in starved primary rat Schwann cells. Importantly, TACE-cleaved NRG1 did not activate p-AKT (Fig. 8c) , unlike BACE1-cleaved NRG1 (Fig. 8d) . This result suggests that TACE and BACE1 differentially activate NRG1, leading to either impairment (TACE) or activation (BACE1) of PI3K signaling and, hence, of myelination in Schwann cells. Furthermore, unlike a lentiviral construct expressing full-length NRG1 type III, a lentiviral construct expressing a cDNA encoding the portion of NRG1 type III from the N terminus to the histidine located between the identified TACE cleavage sites (Fig 7e) , rescued myelination of Nrg1 type III -/-DRGs inefficiently (Fig. 8b) , despite being expressed on the axonal surface (Fig. 8e) .
To further confirm the inhibitory role of TACE on NRG1 type III, we tested whether a cross with Tace +/− mice, whose neurons are myelinated normally, would rescue hypomyelination of Nrg1 type III +/− mice. Morphological analysis of compound Nrg1 type III +/− ; Tace +/− P30 sciatic nerves (Fig. 8f) and g ratio measurements (Fig. 8g and  Supplementary Table 1) showed that a 50% reduction in TACE activity was sufficient to rescue myelination in Nrg1 type III +/− mice.
Taken together, these results provide strong evidence that TACE inhibits myelination by modulating the amount of functional NRG1 type III on axonal membranes. They also describe a newly discovered level of regulation of PNS myelination.
DISCUSSION
In this study, we describe a previously uncharacterized inhibitory mechanism that regulates the extent of myelination in the PNS. As A key finding is that these inhibitory effects of TACE directly oppose those of BACE1 (refs. 3-5), as indicated by differential activation of the PI3K pathway in Schwann cells. TACE inactivation leads to an acceleration of the myelinating program in vitro and in vivo. Together, these data indicate that secretases provide a post-transcriptional control of the amount of functional NRG1 type III and suggest that the balance between BACE1 and TACE activity is a key determinant of the timing and extent of PNS myelination (Supplementary Fig. 9 ).
An important question is how the balance of NRG1 cleavage by these distinct secretases is regulated, including whether cleavage by one secretase precludes processing by the others. The specificity that is achieved by sheddases, which normally process multiple substrates, has not been completely clarified. Several studies have reported that secretases do not recognize a specific amino acid sequence 31 . This complexity is further enhanced by the fact that the same sheddase can process a single protein at different sites, as in the case of APP 32 . Thus, even though this is a highly conserved process, the actual mechanism by which regulated shedding occurs is unknown. Nonetheless, comparisons of the amino acid sequences of different substrates that are cleaved by the same secretase, together with the use of peptide libraries to identify putative consensus cleavage sequences, have helped in the identification of preferential amino acids that are targeted by secretases. Recent studies have reported that TACE selects small aliphatic residues immediately downstream of the cleavage site (P1′ site). Of note, for one of the cleavage sites identified by mass spectrometry, the isoleucine in the P1′ position is among the preferred amino acids for TACE cleavage 31 .
The TACE cleavage site is very close to the previously identified BACE1 cleavage site of NRG1 type III 4 , suggesting that the two processing sites are mutually exclusive. TACE and BACE1 frequently have common substrates, although normally the corresponding cleavage sites are not nearby 33 . TACE-mediated processing and BACE1-mediated processing of NRG1 type III most probably occur at different subcellular locations, further strengthening the possibility that that these two events are distinct. The mature form of TACE is mainly located in the perinuclear space 34 and in the plasma membrane 35 . In addition, TACE and NRG1 colocalize in lipid rafts, where they could interact 36, 37 . By contrast, BACE1 is internalized from the plasma membrane to the endosomal compartments and then recycled to the late Golgi 33, 38 . As NRG1 molecules are glycosylated 39 , they are probably delivered to the plasma membrane through the transGolgi network, where they may be activated by BACE1. Whether BACE1-mediated cleavage of NRG1 type III also occurs in endosomes and determines NRG1 type III recycling or degradation, as in the case of cleavage of APP 40 , is unknown. Further studies are required to establish the identity of the cellular organelles in which NRG1 type III processing occurs, as the different localization could influence NRG1 type III-mediated effects on myelination.
Our study suggests that TACE inhibits myelination by modulating NRG1 type III activity rather than total surface levels. Thus, in the absence of TACE, the active form of NRG1 was upregulated (Fig. 7) . Our results indicate that TACE cleaves NRG1 type III in the β exon of the EGF domain, generating a nonfunctional molecule that inefficiently rescues myelination of Nrg1 type III -/-DRG neurons (Fig. 8) . We suggest that this cleavage affects the affinity of NRG1 type III for the ERBB2-ERBB3 heterodimer, as indicated by enhanced ERBB2-ERBB3-Fc binding in the absence of TACE (Fig. 7) . In agreement with this model, there was more p-AKT in femoral nerves of Tace −/− mice (Fig. 5) , and NRG1 cleaved by TACE did not activate the PI3K pathway in Schwann cells (Fig. 8) . A corollary to these findings is that nearby cleavage of NRG1 by BACE1 enhanced the affinity of NRG1 for ERBB receptors, as suggested by higher levels of AKT phosphorylation (Fig. 8) .
The effects of TACE cleavage are neuron-autonomous. We observed the hypermyelinating phenotype only when Tace was ablated in neurons, further strengthening the likelihood that TACE acts on axonal NRG1 type III. More importantly, this hypermyelination closely resembled that of mice overexpressing Nrg1 type III -/-2 and was due to the higher number of myelin lamellae. In addition, reduced TACE activity was sufficient to rescue myelination in NRG1 type III +/− mice. Further, ablation of neuronal Tace determined aberrant myelination of small-caliber axons that would normally be unmyelinated, probably by altering the threshold levels of expression of axonal NRG1 type III 1 . Finally, inhibition of TACE in Nrg1 type III -/-neurons was not enough to rescue the myelination defect of these neurons, further suggesting that TACE processes NRG1 type III. Nonetheless, we cannot exclude the possibility that TACE might act on a separate molecule that is not functional in Nrg1 type III -/-neurons because it is inactive or absent owing to the absence of NRG1 type III. A likely candidate is Notch1, an inhibitor of myelination 17 , although Notch1 processing is not altered in cocultures of Schwann cells and DRG neurons infected with Tace shRNAs (Supplementary Fig. 2 ). In agreement, it has been shown recently that ADAM10 is the essential protease that regulates Notch1 cleavage, and does so in a ligand-dependent manner, whereas TACE participates in substrate cleavage in a ligand-independent manner 41 .
Surprisingly, defects in the Remak bundles of HB9-cre; Tace fl/fl mice partially resemble those of NRG1 type III +/− mice 1 . Unlike these NRG1-haploinsufficient mice, however, HB9-cre; Tace fl/fl mice were also characterized by unsorted fibers of large diameter, suggesting that TACE cleaves a different substrate in Remak bundles. Of note, MAL-overexpressing mice 42 have similar alterations to and accumulation of p75 NTR , another target of TACE 6 , in nonmyelinating Schwann cells. Accordingly, TACE inhibition altered the processing of p75 NTR . Although we cannot exclude the contribution of p75 NTR , it has been suggested that glia and not axonal p75 NTR promotes myelination in vitro 16 and remyelination in vivo 43 . That TACE might cleave molecules a r t I C l e S other than NRG1 type III that are also implicated in myelination is also suggested by our analyses of Mpz-cre; Tace fl/fl mice and by the reductions in the caliber of myelinated fibers in HB9-cre; Tace fl/fl mice.
In summary, we describe a previously uncharacterized mechanism that controls the regulation of myelination during PNS development, by modulating a signaling pathway. Recent studies suggest that NRG1 type III is dispensable for myelin maintenance but important for remyelination 44, 45 . The question of whether TACE plays a part during myelin maintenance or remyelination will require further investigations. The therapeutic potential of TACE modulation is underscored by the development of several compounds that specifically target TACE and have already been tested in clinical trials for rheumatoid arthritis 46 . Thus, TACE inhibition may be a useful strategy to promote myelination in dysmyelinating peripheral neuropathies.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
